5 active not recruiting. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Frontotemporal Lobar Degeneration: new trials by email Literature Review of Frontotemporal Lobar Degeneration trials Research Report on Frontotemporal Lobar Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP - Cognitively Normal Older Adults, Hypertension | Phase 2 | Active not recruiting | Rong Zhang | 180 | 2022-10-25 | 2026-07-21 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) DNL593, Placebo - Frontotemporal Dementia | Phase 1 / Phase 2 | Active not recruiting | Denali Therapeutics Inc. | 85 | 2022-02-01 | 2026-01-15 |
| Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) LY3884963, Methylprednisolone, Optional Sirolimus - Frontotemporal Dementia | Phase 1 / Phase 2 | Active not recruiting | Prevail Therapeutics | 35 | 2020-11-09 | 2026-07-16 |
| Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD Metformin - C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia | Phase 2 | Active not recruiting | University of Florida | 41 | 2020-01-10 | 2026-08-20 |
Frontotemporal Dementia (4) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Aphasia (1) · Aphasia, Primary Progressive (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Hypertension (1) · Language Disorders (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1) · Pick Disease of the Brain (1)
Brain Diseases (4) · Central Nervous System Diseases (4) · Dementia (4) · Mental Disorders (4) · Metabolic Diseases (4) · Nervous System Diseases (4) · Neurocognitive Disorders (4) · Neurodegenerative Diseases (4) · Nutritional and Metabolic Diseases (4) · Proteostasis Deficiencies (4) · TDP-43 Proteinopathies (4) · Behavior (1) · Cardiovascular Diseases (1) · Communication (1)
Amlodipine (1) · Angiotensin Receptor Antagonists (1) · Calcium Channel Blockers (1) · Losartan (1) · Metformin (1) · Methylprednisolone (1)
Denali Therapeutics Inc. (1) · EIP Pharma Inc (1) · Prevail Therapeutics (1) · Rong Zhang (1) · University of Florida (1)
United States (5) · United Kingdom (3) · Belgium (2) · France (2) · Spain (2) · Australia (1) · Brazil (1) · Colombia (1) · Czechia (1) · Italy (1) · Netherlands (1) · Portugal (1) · Turkey (Türkiye) (1)
Amy Berger, MD (1) · David Zhu, PhD (1) · Laura Ranum, PhD (1) · Rong Zhang, PhD (1) · Travis Lewis, MD, PhD (1) · Wanpen Vongpatanasin, MD (1)
PMID 37624739, PMID 38018119, PMID 38745011
2023 (1), R01AG076660 (1)